6QF9
Structure of an anti-Mcl1 scFv
Summary for 6QF9
Entry DOI | 10.2210/pdb6qf9/pdb |
Related | 6qb3 6qb9 6qf6 |
Descriptor | scFv (2 entities in total) |
Functional Keywords | mcl1, scfv, apoptosis |
Biological source | Homo sapiens |
Total number of polymer chains | 2 |
Total formula weight | 52857.92 |
Authors | Luptak, J. (deposition date: 2019-01-09, release date: 2019-11-06, Last modification date: 2024-11-06) |
Primary citation | Luptak, J.,Bista, M.,Fisher, D.,Flavell, L.,Gao, N.,Wickson, K.,Kazmirski, S.L.,Howard, T.,Rawlins, P.B.,Hargreaves, D. Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1. Acta Crystallogr D Struct Biol, 75:1003-1014, 2019 Cited by PubMed Abstract: Apoptosis is a crucial process by which multicellular organisms control tissue growth, removal and inflammation. Disruption of the normal apoptotic function is often observed in cancer, where cell death is avoided by the overexpression of anti-apoptotic proteins of the Bcl-2 (B-cell lymphoma 2) family, including Mcl-1 (myeloid cell leukaemia 1). This makes Mcl-1 a potential target for drug therapy, through which normal apoptosis may be restored by inhibiting the protective function of Mcl-1. Here, the discovery and biophysical properties of an anti-Mcl-1 antibody fragment are described and the utility of both the scFv and Fab are demonstrated in generating an Mcl-1 crystal system amenable to iterative structure-guided drug design. PubMed: 31692474DOI: 10.1107/S2059798319014116 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.43 Å) |
Structure validation
Download full validation report
